IFNA1 and severe acute respiratory syndrome: In this context, previous studies in SARS-CoV infections reported that IFN-β might be a valid candidate to treat COVID-19, and a recent clinical trial demonstrated that IFN-β1a reduced the duration of patients’ hospital stay and/or ameliorated their clinical status [44].